Drug Sensitivity Analysis and Preliminary Clinical Application Based on Patient-derived Organoid in Oral Squamous Cell Carcinoma

doi:10.13701/j.cnki.kqyxyj.2024.08.010

Abstract

Abstract: Objective: To perform drug sensitivity experiments on patient-derived oral squamous cell carcinoma (OSCC) organoid models and to design individualized drug therapies for the corresponding patients. Mehthods: In the present study, patient-derived organoid (PDO) models were established by obtaining fresh specimens through biopsy or radical operation. These models were used to determine the sensitivity of six drugs (cisplatin, paclitaxel, 5-FU, Cetuximab, Alpelisib, and Nutlin-3) to OSCC. Four of the biopsy patients were given individualized medication according to the experimental results and the short-term therapeutic effect was observed after two courses of treatment. Results: Ten OSCC organoids were successfully established (success rate=10/12, 83.3%) , which could be stably passaged and amplified for more than four generations. The histopathology characteristics of OSCC were highly consistent with those of their parental tumor tissues. The PDO models derived from different patients showed individual differences in the results of drug sensitivity tests. The tumor control results of 4 biopsy patients all met the partial remission criteria, which were consistent with the experimental results. Conclusion: The histopathological characteristics of the established OSCC PDO models were highly similar to those of their parental tumors. The results of the in vitro drug sensitivity tests based on these models were consistent with the clinical treatment response of the corresponding patients, laying a foundation for the establishment of a new individualized and precise drug treatment system for OSCC.

Key words: patient-derived organoid, oral squamous cell carcinoma, in vitro drug sensitivity test, precision therapy, clinical translation

CHEN Lin, CHEN Yinyu, LI Xinran, GE Liangyu, WANG Shoupeng, MENG Jian. Drug Sensitivity Analysis and Preliminary Clinical Application Based on Patient-derived Organoid in Oral Squamous Cell Carcinoma[J]. Journal of Oral Science Research, 2024, 40(8): 715-721.

References

[1] Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1):7-33.
[2] 赵国发,王晓芳,张蕾,等. 药物疗法在头颈部鳞癌治疗中的应用研究进展[J]. 山东医药,2021,61(9):110-115.
[3] 孙树洋,张志愿.基于肿瘤临床前模型建立头颈癌新型药物基因组学的必要性及展望[J].山东大学学报(医学版),2021,59(9):57-63.
[4] Jacob F, Salinas RD, Zhang DY, et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity [J]. Cell, 2020, 180(1):188-204.e22.
[5] Driehuis E, Kretzschmar K, Clevers H, et al. Establishment of patient-derived cancer organoids for drug-screening applications [J]. Nat Protoc, 2020, 15(10):3380-3409.
[6] 类器官药物敏感性检测指导肿瘤精准治疗临床应用专家共识(2022年版)编写专家组.类器官药物敏感性检测指导肿瘤精准治疗临床应用专家共识(2022年版)[J].中国癌症防治杂志,2022,14(3):234-239.
[7] Chow LQM. Head and neck cancer [J]. N Engl J Med, 2020, 382(1):60-72.
[8] Kaidar-Person O, Gil Z, Billan S. Precision medicine in head and neck cancer [J]. Drug Resist Updat, 2018, 40:13-16.
[9] Karakasheva TA, Kijima T, Shimonosono M, et al. Generation and characterization of patient-derived head and neck, oral, and esophageal cancer organoids [J]. Curr Protoc Stem Cell Biol, 2020, 53(1):e109.
[10] Wang HM, Zhang CY, Peng KC, et al. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study [J]. Cell Rep Med, 2023, 4(2):100911.
[11] Driehuis E, Kolders S, Spelier S, et al. Oral mucosal organoids as a potential platform for personalized cancer therapy [J]. Cancer Discov, 2019, 9(7):852-871.
[12] Nair S, Bonner JA, Bredel M. EGFR mutations in head and neck squamous cell carcinoma [J]. Int J Mol Sci, 2022, 23(7):3818.
[13] Vitale I, Shema E, Loi S, et al. Intratumoral heterogeneity in cancer progression and response to immunotherapy [J]. Nat Med, 2021, 27(2):212-224.
[14] LeSavage BL, Suhar RA, Broguiere N, et al. Next-generation cancer organoids [J]. Nat Mater, 2022, 21(2):143-159.
[15] 胡勤刚,赵星星.口腔鳞状细胞癌肿瘤相关成纤维细胞的研究进展[J].口腔医学研究,2020,36(4):309-313.
[16] Wakamatsu T, Ogawa H, Yoshida K, et al. Establishment of organoids from human epithelioid sarcoma with the air-liquid interface organoid cultures [J]. Front Oncol, 2022, 12:893592.
[17] Parikh AS, Yu VX, Flashner S, et al. Patient-derived three-dimensional culture techniques model tumor heterogeneity in head and neck cancer [J]. Oral Oncol, 2023, 138:106330.
[18] Kim SC, Park JW, Seo HY, et al. Multifocal organoid capturing of colon cancer reveals pervasive intratumoral heterogenous drug responses [J]. Adv Sci (Weinh), 2022, 9(5):e2103360.